Tianjin Lisheng Pharmaceutical Co Ltd - Asset Resilience Ratio
Tianjin Lisheng Pharmaceutical Co Ltd (002393) has an Asset Resilience Ratio of 17.92% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Tianjin Lisheng Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Tianjin Lisheng Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 002393 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Tianjin Lisheng Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 002393 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥991.31 Million | 17.92% |
| Total Liquid Assets | CN¥991.31 Million | 17.92% |
Asset Resilience Insights
- Good Liquidity Position: Tianjin Lisheng Pharmaceutical Co Ltd maintains a healthy 17.92% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Tianjin Lisheng Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tianjin Lisheng Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Tianjin Lisheng Pharmaceutical Co Ltd (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Tianjin Lisheng Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.27% | CN¥1.02 Billion ≈ $149.30 Million |
CN¥5.58 Billion ≈ $817.17 Million |
+8.36pp |
| 2024-12-31 | 9.91% | CN¥573.36 Million ≈ $83.90 Million |
CN¥5.79 Billion ≈ $846.60 Million |
+5.91pp |
| 2023-12-31 | 4.00% | CN¥231.26 Million ≈ $33.84 Million |
CN¥5.78 Billion ≈ $845.88 Million |
+0.21pp |
| 2022-12-31 | 3.79% | CN¥200.32 Million ≈ $29.31 Million |
CN¥5.29 Billion ≈ $774.25 Million |
-- |
About Tianjin Lisheng Pharmaceutical Co Ltd
Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China and internationally. The company offers pharmaceutical, traditional Chinese medicine, and antibiotic products in various forms, such as oral solid dosage forms, soft capsules, sterile preparations, and raw materials primarily for cardiovascular and digestive sy… Read more